cores of promising technologies that have been spun out of a university wind up gathering dust, once they’ve been licensed by a pharmaceutical company.

That’s because tech transfer offices often license out technology when it’s still very early stage — and drug makers at times give up trying to validate them.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.